There are currently 30 clinical trials in Celebration, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Celebration and Florida Hospital Celebration Health. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: AdventHealth Celebration, Celebration, Florida
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
NCT05165433
Recruiting
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Moffitt-Advent Health Clinical Research Unit, Celebration, Florida
Conditions: Epithelial Tumor, Metastatic Cancer
Register for Updates
Anovo™ Surgical System - Registry Study
NCT05945433
Recruiting
To collect Real-World Data (RWD) on the ongoing safety and effectiveness of the anovo Surgical system in transvaginal gynecological laparoscopic surgical procedures and to obtain information on the impact of the anovo Skills Development Pathway on user behavior and performance (where performance is measured by the learning curve of the surgeons and procedure outcomes).
Gender:
Female
Ages:
All
Trial Updated:
07/11/2023
Locations: AdventHealth, Celebration, Florida
Conditions: GYN Disorders
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: AdventHealth Celebration, Celebration, Florida
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
NCT05043714
Recruiting
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Moffitt-Advent Health Clinical Research Unit, Celebration, Florida
Conditions: Metastatic Cancer, Epithelial Tumor
Register for Updates
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
NCT04053283
Recruiting
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Moffitt-Advent Health Clinical Research Unit, Celebration, Florida
Conditions: Metastatic Cancer, Epithelial Tumor
Register for Updates